Clinical Scorecard: FDA Selects Seven Companies for Drug Manufacturing Pilot
At a Glance
| Category | Detail |
|---|---|
| Condition | Drug Manufacturing |
| Key Mechanisms | Support domestic pharmaceutical manufacturing and strengthen the US drug supply chain. |
| Target Population | Companies developing new U.S. manufacturing sites for pharmaceuticals. |
| Care Setting | Regulatory and manufacturing environments. |
Key Highlights
- Seven companies selected for the FDA's PreCheck Pilot Program.
- Participants include Amneal, Eli Lilly, and Regeneron among others.
- Program aims to provide early technical feedback to improve facility readiness.
- Launched following a 2025 executive order on domestic drug manufacturing.
- Over 80 requests received for participation in the program.
Guideline-Based Recommendations
Diagnosis
Management
- Companies must propose a new US manufacturing facility addressing market supply needs.
Monitoring & Follow-up
- Early technical guidance and facility-specific Drug Master File review.
Risks
- Pilot does not approve facilities or products in advance, aiming to identify manufacturing issues early.
Patient & Prescribing Data
Patients requiring access to therapies for unmet medical needs.
Facilities must commit to submitting relevant applications (NDA, BLA, ANDA).
Clinical Best Practices
- Engage in facility-focused pre-submission meetings with the FDA.
- Submit facility information through a Drug Master File for review.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
